Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Taraxasterol is a pentacyclic triterpene compound primarily found in dandelion (Taraxacum officinale). Its use in Inflammatory Bowel Disorders (IBD)—including Crohn’s disease and ulcerative colitis—is supported by limited scientific studies, mostly in vitro and animal models. Several preclinical studies have demonstrated that taraxasterol exhibits anti-inflammatory effects by downregulating pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6, as well as inhibiting pathways like NF-κB, which are central to the pathophysiology of IBD. For example, a 2019 study published in Frontiers in Pharmacology showed that taraxasterol alleviated colitis symptoms in mice by reducing inflammation and oxidative stress in colon tissue.

However, clinical trials in humans are lacking, and existing research is insufficient to confirm efficacy or safety in human IBD patients. While the mechanistic data are promising, evidence is currently too preliminary to support clinical use, and no major health organizations recommend taraxasterol for IBD treatment. Its use stems from the general anti-inflammatory properties of dandelion extracts rather than established clinical protocols. In summary, taraxasterol shows potential as an anti-inflammatory agent for IBD in preclinical models, but robust human data are needed to justify its therapeutic use.

More about Taraxasterol
More about Inflammatory Bowel Disorders

Other ingredients used for Inflammatory Bowel Disorders

Other health conditions supported by Taraxasterol

Products containing Taraxasterol